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Background: Simvastatin, 20 mg, plus ezetimibe, 10 mg, daily (simvastatin plus ezetimibe) reduced major
atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart
and Renal Protection (SHARP), but its cost-effectiveness is unknown.
Study Design: Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled trial.
Setting & Population: 9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus
placebo; participants in categories by 5-year cardiovascular risk (low, ,10%; medium, 10%-,20%; or
high, $20%) and CKD stage (3, 4, 5 not on dialysis, or on dialysis therapy).
Model, Perspective, & Timeline: Assessment during SHARP follow-up from the UK perspective; long-term
projections.
Intervention: Simvastatin plus ezetimibe (2015 UK £1.19 per day) during 4.9 years’ median follow-up in
SHARP; scenario analyses with high-intensity statin regimens (2015 UK £0.05-£1.06 per day).
Outcomes: Additional health care costs per major atherosclerotic event avoided and per quality-adjusted
life-year (QALY) gained.
Results: InSHARP, theproportional reductionsper1 mmol/Lof low-density lipoprotein (LDL)cholesterol reduction
with simvastatin plus ezetimibe in all major atherosclerotic events of 20% (95% CI, 6%-32%) and in the costs of
vascular hospital episodes of 17% (95% CI, 4%-28%) were similar across participant categories by cardiovascular
risk and CKD stage. The 5-year reduction in major atherosclerotic events per 1,000 participants ranged from 10 in
low-risk to 58 in high-risk patients and from 28 in CKD stage 3 to 36 in patients on dialysis therapy. The net cost
per major atherosclerotic event avoided with simvastatin plus ezetimibe compared to no LDL-lowering regimen
ranged from £157,060 in patients at low risk to £15,230 in those at high risk (£30,500-£39,600 per QALY); and
from £47,280 in CKD stage 3 to £28,180 in patients on dialysis therapy (£13,000-£43,300 per QALY). In scenario
analyses, generic high-intensity statin regimens were estimated to yield similar benefits at substantially lower cost.
Limitations: High-intensity statin-alone regimens were not studied in SHARP.
Conclusions: Simvastatin plus ezetimibe prevented atherosclerotic events in SHARP, but other less costly
statin regimens are likely to be more cost-effective for reducing cardiovascular risk in CKD.
Am J Kidney Dis. 67(4):576-584. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Cost-effectiveness of LDL-Lowering in CKDThe KDIGO (Kidney Disease: Improving Global
Outcomes) clinical practice guideline for lipid man-
agement in CKD recommends that treatment with a
statin, or a statin plus ezetimibe, be initiated in all non–
dialysis-dependent and nontransplantation patients
with CKD who are 50 years or older, as well as in
younger patients with elevated cardiovascular risk.2 In
the United Kingdom, the National Institute for Health
and Care Excellence recommends atorvastatin, 20 mg,
daily (available generically) for all patients with
CKD.3 Similarly, the 2013 American College of Car-
diology and American Heart Association guidelines
recommend statin therapy for non–dialysis-dependent
patients with CKD who are at increased risk for car-
diovascular disease.4
Although SHARP provided clear evidence that
simvastatin plus ezetimibe is effective for the
prevention of major atherosclerotic events in patients
with CKD, little information is available about its
cost-effectiveness.5 We therefore assess the cost-
effectiveness of simvastatin, 20 mg, plus ezetimibe,
10 mg, daily during the study scheduled treatment
period and the extent to which its cost-effectiveness
varies in relation to the cardiovascular risk of such
patients, the severity of kidney disease, and the cost of
treatment. The relevance of other high-intensity statin
regimens is investigated in scenario analyses.
METHODS
Study Design
Details of the SHARP design and its main results have
been reported previously.1,6 SHARP was registered at
ClinicalTrials.gov (study number: NCT00125593). Patients 40
years or older with CKD but without known coronary heart disease
were eligible if they were receiving maintenance dialysis or
had serum or plasma creatinine levels of at least 150 mmol/L
(1.7 mg/dL) in men or 130 mmol/L (1.5 mg/dL) in women. Partici-
pants randomly assigned to simvastatin plus ezetimibe versus pla-
cebo (Fig S1, available as online supplementary material) were to be
seen in the study clinics at least once every 6 months for at least 4
years. Adherence to study treatment was assessed at each follow-up,
and the use of any nontrial lipid-lowering medication was recorded.
Central laboratory assays of lipid proﬁles were conducted in all
study participants at randomization and at the 2.5-year visit. At each
follow-up visit, information was recorded about any suspected
myocardial infarction, stroke, vascular procedure, cancer, hospital
admission for other reasons, or other serious adverse event. Further
information was sought from the participant, his or her physician, or
hospital records and other sources.
Because the cost-effectiveness of treatments that reduce LDL
cholesterol levels in other populations is strongly determined by
the cardiovascular risk of such populations,7 we developed a Cox
proportional hazards risk-prediction model8 to categorize SHARP
patients according to whether their 5-year risk for cardiovascular
events (deﬁned as nonfatal myocardial infarction, nonfatal stroke,
any revascularization procedure, or vascular death) was low
(,10%), medium (10%-,20%), or high ($20%; Table S1).
Assessment of Health Outcomes and Health Care Costs
The cost-effectiveness analysis is performed for the period from
randomization (to simvastatin plus ezetimibe vs placebo) until theAm J Kidney Dis. 2016;67(4):576-584ﬁnal study visit (ie, 4.9 years’ median follow-up). The prespeciﬁed
health outcome in the cost-effectiveness analysis was major
atherosclerotic event (myocardial infarction or death from coro-
nary heart disease, nonhemorrhagic stroke, or arterial revascular-
ization excluding dialysis access procedures), the key end point in
SHARP.1,9 The cost-effectiveness analysis was developed from
the perspective of the UK National Health Service (NHS), and all
calculations are based on applying UK NHS costs to health care
resource use recorded in the study. All major atherosclerotic
events and other serious adverse events recorded during the study
(ie, not just the ﬁrst event of any particular type) were included. To
estimate the cost of hospital care, hospital episodes were mapped
onto UK Healthcare Resource Groups or onto hospital specialty
for some outpatient episodes, with costs in 2011 UK pounds (£).
Hospital episodes were classiﬁed into 1 of 4 categories: (1)
atherosclerotic (including coronary, cerebrovascular, revasculari-
zation, and other vascular atherosclerotic), (2) nonatherosclerotic
vascular, (3) renal, or (4) other (nonvascular and nonrenal). When
a hospital episode involved serious adverse events in more than 1
category, the episode was classiﬁed hierarchically according to the
above mentioned order. The cost of routine dialysis was calculated
based on dialysis status and modality recorded for participants
during the study, using the UK recommended frequency of
dialysis sessions10 and average cost per session.11
Participants allocated to simvastatin plus ezetimibe who were
recorded at a scheduled follow-up as having taken $10% of their
allocated study treatment were attributed a daily simvastatin plus
ezetimibe cost of £1.19 (2015 UK price)12 over that follow-up
period. It was assumed that participants taking ,10% of the
medication would not obtain a repeat prescription in ordinary
clinical practice, so no cost was attributed to such patients while
adherence remained at that level. Use of nonstudy medication, by
category, was compared between treatment arms at 2.5 years using
Pearson c2 test. To improve the precision of cost-effectiveness
estimates, only categories of hospital episodes and other health
care use for which there were statistically signiﬁcant effects of
allocation to study treatment were included in cost-effectiveness
analyses.
Cost-effectiveness Analyses
Intention-to-treat analyses assessed the effects of allocation to
simvastatin plus ezetimibe on major atherosclerotic events, rate of
hospital episodes, and costs of hospital episodes for the duration of
follow-up among all patients with CKD randomly assigned to
simvastatin plus ezetimibe versus placebo in SHARP, as well as
in patient categories by 5-year cardiovascular risk and CKD stage
(3, 4, 5 not on dialysis, or on dialysis therapy). Quasi-Poisson
models with sandwich standard errors13 were used to estimate
rate ratios (RRs) for different outcomes, and standard c2 tests for
heterogeneity or trend were used to examine differences in RRs
between different categories of patients. In randomized trials of
statin regimens14,15 and ezetimibe,16 the proportional reductions in
major atherosclerotic events achieved by different regimens are
proportional to the absolute reduction in LDL cholesterol level
achieved. Because the LDL cholesterol level reduction achieved
with simvastatin plus ezetimibe in speciﬁc patient subgroups in
SHARP was inﬂuenced by baseline LDL cholesterol level in that
subgroup, as well as the degree of adherence to allocated treatment
and use of nonstudy statin therapy,1 RRs for each outcome were
adjusted for such differences and are presented as RRs per 1 mmol/
L of LDL cholesterol reduction (as measured at the study
midpoint). In the absence of statistically signiﬁcant heterogeneity
of the effects of treatment on major atherosclerotic events per
1-mmol/L reduction in LDL cholesterol level across categories of
participants, the absolute reduction in such events in a particular
subgroup was derived by applying the overall proportional reduc-
tion in this outcome (ie, among all SHARP participants)577
Mihaylova et alcorresponding to the achieved LDL cholesterol reduction in
the respective subgroup to the rate among placebo-allocated pa-
tients in that subgroup. Subgroup-speciﬁc absolute reductions in
vascular hospital episode costs were calculated in an analogous
way. The cost of simvastatin plus ezetimibe for a particular sub-
group was based on the level of use required to achieve the
observed LDL cholesterol level reduction in that subgroup. The net
cost of treatment for each subgroup was calculated by subtracting
the estimated hospital cost savings from the cost of simvastatin plus
ezetimibe. Division of these net costs by the absolute reduction in
major atherosclerotic events yielded cost-effectiveness estimates
(net costs per major atherosclerotic event avoided).
Cost-effectiveness results are presented for the reductions in
LDL cholesterol levels actually observed in SHARP (ie, incorpo-
rating actual nonadherence and use of nonstudy statin treatment).
Future costs and outcomes were discounted at 3.5% per annum.17 A
bootstrap procedure was used to evaluate the stochastic uncertainty
in cost-effectiveness results,18 and the 95% conﬁdence intervals
(CIs) for events avoided, additional costs, and cost-effectiveness
were evaluated using the percentile method.
Sensitivity Analyses
Sensitivity analyses assessed the cost-effectiveness of simva-
statin plus ezetimibe treatment based on treatment costs ranging
from the current UK simvastatin plus ezetimibe price of £1.19 per
day to the cost of a UK generic statin regimen that produces a
similar proportional reduction in LDL cholesterol level (eg, £0.05-
£0.10 per day12; Table S2). Cost-effectiveness was also assessed
under an assumption of full adherence with treatment. The net
costs per major vascular event (major atherosclerotic event, non-
coronary cardiac death [eg, nonischemic heart failure, valvular
heart disease, and arrhythmic cardiac death], or hemorrhagic
stroke) avoided were also calculated. Finally, the cost-
effectiveness of simvastatin plus ezetimibe among dialysis pa-
tients was also evaluated using the point estimate for such patients
in SHARP because meta-analyses suggest that the effects of LDL
cholesterol lowering in a dialysis population may be smaller than
in other patients with CKD.19-21
Long-term Projections
To assess the effects of avoiding major atherosclerotic events
during SHARP on quality-adjusted survival and end-stage renal
disease (ESRD) costs, separate Gompertz proportional hazards
parametric survival models were ﬁtted to participants having and
not having major atherosclerotic events during SHARP (matched
by their 5-year estimated cardiovascular risk22), and median
overall survival was then calculated by cardiovascular risk and
CKD stage category. The differences between these survival times
provided the projected gains in survival due to avoiding a major
atherosclerotic event. Quality of life during projected survival was
based on stage of CKD,5 and ESRD costs were calculated using
rates of progression to ESRD by CKD stage estimated in
SHARP23 and assuming a 2:1 ratio between dialysis and trans-
plantation and annual ESRD costs.24
Other High-Intensity Statin Regimens
Although the effectiveness of regimens other than simvastatin
plus ezetimibe was not assessed directly in SHARP, we conducted
scenario analyses with other high-intensity statin regimens that can
achieve a 40% or higher LDL cholesterol reduction.3 Table S2
summarizes the reductions in LDL cholesterol level achieved
with such regimens and their UK daily cost. Based on the known
linear relationship between mean absolute LDL cholesterol
level reduction and risk reduction in a wide range of patients in a
meta-analysis of large statin trials14 and in a trial of ezetimibe
added to a statin regimen,16 we calculated the likely reductions in
major atherosclerotic events with different regimens by scaling the578proportional reduction observed in SHARP by the ratios of pro-
portional reductions in LDL cholesterol level achieved (Table S2).
Further detail on methods is available in Item S1.RESULTS
Effects of Randomized Allocation to Simvastatin plus
Ezetimibe in SHARP
Overall, 9,270 patients from 18 countries were
randomly assigned to simvastatin plus ezetimibe
(4,650 patients) versus placebo (4,620 patients) in
SHARP. Baseline characteristics of participants,
subdivided by estimated cardiovascular risk and
CKD stage, are shown in Table 1. Allocation to
simvastatin plus ezetimibe produced a mean reduc-
tion of 0.85 mmol/L in LDL cholesterol level, which
yielded a 17% proportional reduction (rate ratio
[RR], 0.83; 95% CI, 0.72-0.95; P 5 0.007) in all
(ﬁrst and subsequent) major atherosclerotic events,
corresponding to a 20% proportional reduction (RR,
0.80; 95% CI, 0.68-0.94) per 1-mmol/L LDL
cholesterol level reduction (Fig 1). After allowing
for differences in LDL cholesterol levels achieved
(Table S3), there was no signiﬁcant heterogeneity of
this reduction across categories by cardiovascular
risk (P for heterogeneity 5 0.9) and no signiﬁcant
trend toward smaller proportional reductions with
more severe CKD stage (P for trend 5 0.3; Fig 1).
Overall, allocation to simvastatin plus ezetimibe
yielded a 16% proportional reduction (RR, 0.84; 95%
CI, 0.74-0.96; P 5 0.01) in atherosclerotic hospital
episodes and an 11% reduction (RR, 0.89; 95% CI,
0.79-0.99; P 5 0.04) in nonatherosclerotic vascular
episodes (Table S4). These effects resulted in a 15%
proportional reduction (RR, 0.85; 95% CI, 0.75-0.97;
P 5 0.01) in mean costs of all vascular hospital epi-
sodes (corresponding to 17% proportional reduction
[RR, 0.83; 95% CI, 0.72-0.96] per 1-mmol/L LDL
cholesterol reduction), with no signiﬁcant heteroge-
neity of the proportional reduction in costs among
subgroups deﬁned by 5-year risk of cardiovascular
disease (P for heterogeneity 5 0.2) or by CKD stage
(P for trend 5 0.9; Fig 2). The number of vascular
hospital episodes (ie, episodes that included any
vascular event) by case-mix group or specialty and
the respective unit costs are presented in Table S5.
Allocation to simvastatin plus ezetimibe had no
signiﬁcant effect on renal hospital episodes (RR, 0.97;
95% CI, 0.90-1.03; P 5 0.3) or other nonvascular and
nonrenal hospital episodes (RR, 1.03; 95% CI, 0.97-
1.09; P 5 0.4; Table S4), so the costs of both were
excluded from subsequent calculations of cost-
effectiveness. Similarly, there were no signiﬁcant
differences in the costs of routine dialysis or in the use
of medications other than nonstudy lipid-lowering
medications, so these costs were also excluded.Am J Kidney Dis. 2016;67(4):576-584
Table 1. Baseline Characteristics of SHARP Participants by CVD Risk and CKD Stage at Randomization
Overall
N 5 9,270
By 5-year Risk of CVD By CKD Stage
,10%
(n 5 2,489)
10%-,20%
(n 5 2,997)
$20%
(n 5 3,784)
3a
(n 5 2,323)
4b
(n 5 2,663)
5c
(n 5 1,259)
On dialysis
(n 5 3,025)
Age, y 626 12 52 6 8 61 6 11 69 6 10 63 6 12 63 6 12 62 6 12 60 6 12
Male sex 5,800 (63) 1,206 (48) 1,915 (64) 2,679 (71) 1,691 (73) 1,562 (59) 629 (50) 1,918 (63)
Current smoker 1,243 (13) 237 (10) 443 (15) 563 (15) 299 (13) 330 (12) 142 (11) 472 (16)
Previous vascular
disease
1,393 (15) 44 (2) 173 (6) 1,176 (31) 343 (15) 400 (15) 189 (15) 461 (15)
Diabetes mellitus 2,091 (23) 106 (4) 388 (13) 1,597 (42) 557 (24) 611 (23) 255 (20) 668 (22)
Body mass index,
kg/m2
27.1 6 5.6 26.9 6 5.5 27.16 5.6 27.2 6 5.7 27.76 5.1 27.5 6 5.7 26.56 5.4 26.56 5.9
Cholesterol
Total, mmol/L 4.896 1.18 5.05 6 1.08 4.91 6 1.14 4.76 6 1.26 5.05 6 1.13 5.096 1.15 4.79 6 1.24 4.63 6 1.17
HDL, mmol/L 1.126 0.34 2.89 6 0.82 2.78 6 0.86 2.69 6 0.91 1.14 6 0.34 1.146 0.34 1.11 6 0.33 1.08 6 0.35
LDL, mmol/L 2.786 0.87 1.13 6 0.33 1.13 6 0.35 1.06 6 0.33 2.91 6 0.85 2.926 0.85 2.696 0.9 2.58 6 0.86
Triglycerides, mmol/L 2.326 1.72 2.26 6 1.47 2.34 6 1.57 2.35 6 1.97 2.43 6 1.95 2.356 1.45 2.09 6 1.43 2.32 6 1.85
Diastolic BP, mm Hg 796 13 82 6 12 80 6 13 77 6 13 80 6 13 80 6 13 80 6 12 786 13
Systolic BP, mm Hg 1396 22 1326 18 1386 21 144 6 23 1396 20 1396 21 1416 21 1386 24
5-year risk of CVD
,10% 2,489 (27) 995 (43) 873 (33) 285 (23) 336 (11)
10%-,20% 2,997 (32) 769 (33) 915 (34) 366 (29) 947 (31)
$20% 3,784 (41) 559 (24) 875 (33) 608 (48) 1,742 (58)
Note: Values for categorical variables are given as number (percentage); for continuous variables, as mean 6 standard deviation.
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SHARP, Study of Heart and Renal Protection.
aeGFR$ 30 mL/min/1.73 m2. 83% of participants in this category with CKD stage 3b (eGFR 30-45 mL/min/1.73 m2).
beGFR of 15 to ,30 mL/min/1.73 m2.
ceGFR , 15 mL/min/1.73 m2; not on dialysis therapy.
Cost-effectiveness of LDL-Lowering in CKDThe mean cost per patient of simvastatin plus ezeti-
mibe required to achieve the LDL cholesterol level
reduction actually observed in SHARP during the
study follow-up was £1,319 6 £11 (standard error;
Table 2). There was a trend toward lower costs ofFigure 1. Effect of allocation to simvastatin plus ezetimibe treatmen
Renal Protection). 183% of participants in this category with chronic kid
30-,45 mL/min/1.73 m2). Abbreviations: CI, confidence interval; CVD,
Am J Kidney Dis. 2016;67(4):576-584treatment among those at higher 5-year risk for car-
diovascular disease. This was attributable to shorter
duration of treatment among those at higher risk
for death; for example, in the highest and lowest risk
groups, the costs of study simvastatin plus ezetimibet on all major atherosclerotic events in SHARP (Study of Heart and
ney disease (CKD) stage 3b (estimated glomerular filtration rate of
cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.
579
Figure 2. Effect of allocation to simvastatin plus ezetimibe treatment on costs of vascular hospital episodes in SHARP (Study of
Heart and Renal Protection). 183% of participants in this category with chronic kidney disease (CKD) stage 3b (estimated glomerular
filtration rate of 30-,45 mL/min/1.73 m2). Abbreviations: CI, confidence interval; CVD, cardiovascular disease; LDL-C, low-density
lipoprotein cholesterol; SE, standard error.
Mihaylova et alwere £1,137 6 £16 and £1,570 6 £20, respectively,
reﬂecting mean treatment durations of 1,0386 15
and 1,400 6 18 days, respectively.
Because CKD stage and estimated cardiovascular
risk were correlated (Table 1), the cost per patient
was lowest among those with more severe CKD
(£1,182 6 £29 among those at stage 5 not on dialysis
therapy and £1,214 6 £20 among those on dialysis
therapy) and highest among those with CKD stage 3
(£1,454 6 £20).
Base-Case Cost-effectiveness Results
Among all randomly assigned patients, 37 major
atherosclerotic events were avoided per 1,000 partic-
ipants allocated to simvastatin plus ezetimibe over
about 5 years, and the net cost of treatment to achieve
the reduction in LDL cholesterol levels observed in
SHARP (ie, simvastatin plus ezetimibe cost minus
vascular hospital episode cost saving) was £1,142
(95% CI, £1,004-£1,282); the overall cost-
effectiveness of simvastatin plus ezetimibe was
£30,390 per major atherosclerotic event avoided
(Table 3). Taking into account the absolute rates of
major atherosclerotic events and costs of vascular
hospital episodes among placebo-allocated partici-
pants across the participant subgroups, the reduction
in major atherosclerotic events per 1,000 participants
ranged from 10 in low-risk to 58 in high-risk patients
and from 28 in patients with CKD stage 3 to 36 in
patients on dialysis therapy at randomization. The net
cost of avoiding a major atherosclerotic event ranged
from £157,060 (95% CI, £84,090-£597,940) among
patients at low cardiovascular risk to £15,230
(95% CI, £7,220-£64,410) among patients at high
risk (Table 4) and from £47,280 (95% CI,580£26,370-£173,760) among patients in CKD stage 3 to
£28,180 (95% CI, £13,820-£115,380) among patients
on dialysis therapy. Similar results were obtained in
analyses of major vascular events (Fig S2; Table S6).
Sensitivity Analyses
The cost-effectiveness of simvastatin plus ezeti-
mibe was very sensitive to drug price (Fig 3), with net
cost per major atherosclerotic event decreasing nearly
linearly with lower price. Full adherence with sim-
vastatin plus ezetimibe would achieve larger treat-
ment beneﬁts but would also incur additional
treatment costs, so full adherence would result in only
a slight reduction in incremental cost-effectiveness
ratios (Tables S6 and S7).
Calculation of the cost-effectiveness of simva-
statin plus ezetimibe among dialysis patients, based
on the point estimate for the treatment effect among
dialysis patients only (ie, 8% [95% CI, 214% to
25%] reduction in major atherosclerotic events and
12% [95% CI, 26% to 27%] reduction in costs of
vascular hospital episodes; Figs 1 and 2) produced a
nonsigniﬁcant 22 (95% CI, 238 to 80) major
atherosclerotic events avoided per 1,000 at a net
cost per event avoided of £45,880, with the 95%
CI spreading both across areas of net health beneﬁt
and harm.
Net Cost per Quality-Adjusted Life-Year
Estimated differences in median survival due to
avoiding a major atherosclerotic event ranged from 12
years (8.9 quality-adjusted life-years [QALYs])
among those at low cardiovascular risk to 1.9 years
(1.4 QALYs) among those at high risk and from 7.1
years (6.2 QALYs) among those in CKD stage 3 toAm J Kidney Dis. 2016;67(4):576-584
Table 2. Average Number of Days’ Exposure to and Cost of
Study Simvastatin plus Ezetimibe per Patient, by CVD Risk and
CKD Stage at Randomization
Study Simvastatin
plus Ezetimibe
Cost to
Achieve
LDL-C
Reductions
Observed in
SHARPaDays Cost
By 5-year risk of CVD
,10% 1,4006 18 £1,665 6 £21 £1,5706 £20
10%-,20% 1,2366 17 £1,471 6 £20 £1,3806 £19
$20% 1,0386 15 £1,235 6 £18 £1,1376 £16
By CKD stage
3b 1,3336 18 £1,586 6 £22 £1,4546 £20
4 1,2896 17 £1,534 6 £21 £1,4496 £20
5c 1,0646 26 £1,266 6 £31 £1,1826 £29
On dialysis 1,0776 18 £1,282 6 £21 £1,2146 £20
All patients 1,2006 10 £1,428 6 £12 £1,3196 £11
Note: Values are given as average 6 standard error. Simva-
statin plus ezetimibe at UK £1.19 per day (2015).
Abbreviations: CKD, chronic kidney disease; CVD, cardio-
vascular disease; LDL-C, low-density lipoprotein cholesterol;
SHARP, Study of Heart and Renal Protection.
aActual use of study simvastatin plus ezetimibe treatment
adjusted to the use needed to achieve the LDL cholesterol level
reductions observed in SHARP in the absence of other lipid-
lowering treatments. For example, 57% of participants on dial-
ysis therapy at randomization allocated to simvastatin plus ezeti-
mibe were taking their study treatment at 2.5 years (and average
study simvastatin plus ezetimibe cost for a participant on dialysis
therapy at randomizationwas £1,282), but net use of any (including
nonstudy) lipid-lowering treatment between study treatment arms
at 2.5 years was 54%. Therefore, the cost of simvastatin plus
ezetimibe needed to achieve the observed LDL cholesterol levels
in this patient group was calculated as £1,282 3 [54%/57%] 5
£1,214.
b83% of participants in this category with CKD stage 3b
(estimated glomerular filtration rate of 30-,45 mL/min/1.73 m2).
cNot on dialysis therapy.
Cost-effectiveness of LDL-Lowering in CKD3.4 years (2.4 QALYs) among those in receipt of
dialysis therapy at randomization. During this added
survival time, additional ESRD costs in the range of
£23,500 to £154,300 across vascular risk groups and
£20,800 to £54,100 across CKD stages were pro-
jected. In the base-case cost-effectiveness analysis,
the use of simvastatin plus ezetimibe for about 5 years
in SHARP is projected to result in net costs of
£30,500 to £39,600 per QALY across risk groups and
£13,000 to £43,300 per QALY across CKD stages
(Tables 4 and S8).
Scenario Analyses of Relevance of Other
High-Intensity Statin Regimens
For scenario analyses, we assumed that high-
intensity statin regimens other than simvastatin plus
ezetimibe would achieve effects on major atheroscle-
rotic events and hospital costs that were in proportionAm J Kidney Dis. 2016;67(4):576-584to their relative potency in reducing LDL cholesterol
levels compared to simvastatin plus ezetimibe (see
Methods and Table S2), and that they would not result
in additional adverse effects. The net cost per major
atherosclerotic event avoided with such a regimen
would be similar to simvastatin plus ezetimibe if it
were available at identical cost (Fig 3). Table 4 sum-
marizes the projected net cost per QALY for high-
intensity statins at different costs. For example, with
atorvastatin, 20 mg, daily (£0.05 per day), the net cost
per QALY would be £12,700 to £17,300 across the
vascular risk categories and £3,100 to £20,100
across CKD stages (Table 4).
DISCUSSION
Compared to no LDL cholesterol–lowering ther-
apy, the net cost per major atherosclerotic event
avoided among SHARP patients with about 5 years
of treatment with simvastatin plus ezetimibe at a UK
2015 cost of £1.19 per day ranged from £15,230 in
those at high risk for cardiovascular disease to
£157,060 in those at low risk (about £30,500-£39,600
per QALY gained) and from £47,280 in those with
CKD stage 3 to £28,180 in those on dialysis therapy
(£13,000-£43,300 per QALY). The Improved
Reduction of Outcomes: Vytorin Efﬁcacy Interna-
tional Trial (IMPROVE-IT) trial of simvastatin plus
ezetimibe versus simvastatin alone among patients
with acute coronary syndromes16 has shown that
the beneﬁt of ezetimibe on major atherosclerotic
events is equivalent to that which can be achieved by
the same LDL cholesterol level reduction with a
statin.14 Therefore, the beneﬁts observed in SHARP
are likely to be possible using a statin regimen that
produces a comparable LDL cholesterol level reduc-
tion (as long as such a regimen does not yield addi-
tional adverse effects). Our scenario analyses using
SHARP data and modeling use of alternative high-
intensity generic statin regimens at a UK 2015 cost
of £0.05 to £0.10 per day suggested that they would
be the most cost-effective option for patients with
CKD. Although the costs of generic statin regimens
might be greater in other countries (eg, generic ator-
vastatin, 20 mg, available at $0.15 per day in the
United States25), it is still likely at present that
such regimens, when available, will be a more cost-
effective means than simvastatin plus ezetimibe
($6.92 per day in the United States25) for reducing
cardiovascular risk in patients with CKD.
One would expect the observed decrease in vascular
events to also affect primary care and outpatient
resource use, but these data were not collected sys-
tematically in SHARP. Nevertheless, the expense of
those services would probably be small in comparison
to the hospital costs and unlikely to materially
affect the estimates presented here.26 In SHARP,581
Table 3. Net Cost to Avoid a Major Atherosclerotic Event with Simvastatin plus Ezetimibe in SHARP
Major Atherosclerotic
Events Avoideda [A]
Simvastatin plus
Ezetimibe Costsb [B]
Vascular Hospital
Cost Savingsb [C]
Net Cost per Major
Atherosclerotic Event Avoidedc
[(B-C)/(A/1,000)]
By 5-year risk of CVD
,10% 10 (3-18) £1,570 (£1,531-£1,609) £78 (£19-£151) £157,060 (£84,090-£597,940)
10%-,20% 24 (7-43) £1,380 (£1,342-£1,417) £141 (£34-£261) £50,300 (£27,130-£190,060)
$20% 58 (17-104) £1,137 (£1,104-£1,169) £244 (£56-£455) £15,230 (£7,220-£64,410)
By CKD stage
3d 28 (3-18) £1,454 (£1,416-£1,492) £113 (£28-£209) £47,280 (£26,370-£173,760)
4 39 (11-69) £1,449 (£1,409-£1,487) £173 (£42-£317) £32,020 (£17,240-£120,720)
5e 35 (9-67) £1,182 (£1,125-£1,238) £154 (£36-£302) £29,210 (£14,170-£120,450)
On dialysis 36 (10-65) £1,214 (£1,175-£1,253) £193 (£44-£369) £28,180 (£13,820-£115,380)
All patients 37 (11-65) £1,319 (£1,298-£1,341) £177 (£42-£326) £30,390 (£16,050-£117,910)
Note: Values are given as value (95% confidence interval). Simvastatin plus ezetimibe at UK £1.19 per day (2015).
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; SHARP, Study of Heart and Renal Protection.
aPer 1,000 treated for about 5 years.
bOver about 5 years per patient.
cWith costs and events discounted at 3.5% per annum.
d83% of participants in this category with CKD stage 3b (estimated glomerular filtration rate of 30-,45 mL/min/1.73 m2).
eNot on dialysis therapy.
Mihaylova et alsimvastatin plus ezetimibe did not have statistically
signiﬁcant effects on costs related to nonvascular
events, to non–lipid lowering concomitant medica-
tions, or to routine maintenance dialysis during
the study, so these costs were excluded in order to
improve the precision of cost-effectiveness estimates.Table 4. Projected Net Costs per QALY of 5-year LDL Lowering
With High-Intensity Statin-Based Regimens Compared to no
LDL Lowering in CKD
Simvastatin
plus
Ezetimibe:
UK £1.19/
daya
High-Intensityb Statins
UK £0.60-£1.10/
dayc
UK £0.05-£0.10/
dayc
By 5-year risk of CVD at start of treatment
,10% £39,600 £30,900-£36,300 £17,300-£18,100
10%-,20% £30,500 £24,800-£28,400 £15,800-£16,300
$20% £33,300 £25,300-£30,200 £12,700-£13,400
By CKD stage at start of treatment
3d £13,000 £9,100-£11,500 £3,100-£3,400
4 £22,400 £18,000-£20,800 £11,100-£11,500
5e £43,300 £33,400-£39,500 £17,900-£18,800
On dialysis £42,700 £34,000-£39,400 £20,100-£20,900
Note: Costs and outcomes discounted at 3.5% per annum.
Abbreviations: CKD, chronic kidney disease; CVD, cardio-
vascular disease; LDL, low-density lipoprotein; QALY, quality-
adjusted life-year.
aBased on 20 mg simvastatin, 10 mg ezetimibe.
bAchieving $40% reductions in LDL cholesterol level.
cSee Table S2 for high-intensity statin-based regimens in the
United Kingdom in this cost range.
d83% of participants in this category with CKD stage 3b
(estimated glomerular filtration rate of 30-,45 mL/min/1.73 m2).
eNot on dialysis therapy.
582Likewise, the costs of laboratory monitoring (and staff
time reviewing laboratory ﬁndings) were also not
included in these cost-effectiveness analyses because
routine monitoring of lipid levels and safety (eg, for
creatine kinase or hepatic enzyme elevations) is not
required for statin-based treatments.2,4 Moreover,
because patients with moderate to severe CKD are
seen regularly in the clinic, any services related to the
prescription of lipid-lowering medications are likely
to take place in the context of a routine consultation.
Estimated professional dispensing fees equate to
w£0.02 per day,12 so dispensing costs would also
have had minimal effect on the cost-effectiveness
estimates. Hospital resource use may have varied
across the 18 countries that participated in SHARP,
but because the present analyses use randomized
comparisons of hospital episodes and UK Healthcare
Resource Groups costs to value them, this is unlikely
to have materially affected our results. Finally, meta-
analyses of randomized trials conducted in a broad
range of patients, including those at high risk for car-
diovascular disease, indicate that the absolute excess
risks of the known or probable adverse effects of statin
therapy (speciﬁcally myopathy, new-onset diabetes
mellitus, and hemorrhagic stroke) are substantially
smaller than the absolute beneﬁts, so the impact of
adverse effects on cost-effectiveness is likely to be
small.27
Because SHARP did not provide deﬁnite evidence
that the proportional effects of reducing LDL
cholesterol levels varied with initial CKD stage, the
cost-effectiveness of simvastatin plus ezetimibe
among dialysis patients was estimated using the
treatment effect estimated among all SHARP patientsAm J Kidney Dis. 2016;67(4):576-584
AB
Figure 3. Net cost per major atherosclerotic event avoided
in SHARP (Study of Heart and Renal Protection) with simva-
statin, 20 mg, plus ezetimibe, 10 mg, daily at different prices
in patients (A) at different cardiovascular disease risk and (B)
at different stages of chronic kidney disease (CKD). Negative
figures indicate cost savings. 183% of participants in this cate-
gory with CKD stage 3b (estimated glomerular filtration rate of
30-,45 mL/min/1.73 m2).
Cost-effectiveness of LDL-Lowering in CKD(ie, a 17% proportional reduction in major athero-
sclerotic events and 15% reduction in vascular hos-
pital costs). However, several meta-analyses have
suggested that the proportional effects of treatment
may be smaller among dialysis patients.19-21 If the
true effects of simvastatin plus ezetimibe (or other
high-intensity statin regimens) among dialysis pa-
tients on such outcomes are similar to the subgroup-
speciﬁc effect observed in SHARP, somewhat
smaller beneﬁts could be expected at higher net cost
per event avoided with a much wider CI.
The cost-effectiveness estimates in the present
report are for treatment health effects and treatment
costs just within a 5-year period, but longer term
treatment would yield larger beneﬁts. Quantiﬁcation of
such gains requires allowance for longer term use and
cost of interventions and effect over time of all renal
and cardiovascular events, as well as for increasing
age, because the rapid increase in vascular disease risk
with older age is offset by a decrease in life expec-
tancy. Further analyses of SHARP using a simulation
model are examining the cost-effectiveness of long-
term use of statin-based regimens.Am J Kidney Dis. 2016;67(4):576-584ACKNOWLEDGEMENTS
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